Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim - SYGNIS Pharma

Next Previous
X
Search
Drug Profile

Filgrastim - SYGNIS Pharma

Alternative Names: AX200; G-CSF - SYGNIS Pharma

Latest Information Update: 12 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Developer SYGNIS Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Spinal cord injuries

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Spinal cord injuries; Stroke

Most Recent Events

  • 25 Jul 2012 Discontinued - Preclinical for Amyotrophic lateral sclerosis in European Union (IV)
  • 25 Jul 2012 Discontinued - Preclinical for Spinal cord injuries in European Union (IV)
  • 14 Feb 2012 Discontinued - Phase-II for Stroke in Austria (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top